Choose Your Country or Region

research use only

Ifosfamide DNA/RNA Synthesis inhibitor

Name: Ifosfamide
Brand: Selleck Chemicals
SKU: S1302
Availability: InStock
Rating: 5 (20 reviews)

Catalog No.S1302 Purity:99.96%

Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer. This compound is typically administered intravenously and undergoes metabolic activation in the liver to produce its active alkylating species. The primary mechanism of action of this agent involves cross-linking DNA strands, thereby inhibiting DNA replication and transcription, which leads to cell death. Due to its potential for causing hemorrhagic cystitis, this medication is often used in combination with mesna, a uroprotectant agent. The clinical use of this chemical includes treatment of various cancers, such as germ cell tumors, soft tissue sarcomas, and lymphomas. Despite its efficacy, this drug is associated with several side effects, including myelos

Chemical Structure

Molecular Weight: 261.09

Purity & Quality Control

Batch: Purity: 99.96%

99.96

Related Products

Related Targets	tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase	Click to Expand
Related Products	CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 Carmofur Triapine (3-AP) B02 BMH-21 YK-4-279 Bergapten Tegafur (FT-207) Azaguanine-8 Halofuginone Adenine HCl Mizoribine Cyclocytidine HCl Thymidine APX-3330 Nedaplatin 6-Thio-dG	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Apoptosis Compound Library DNA Damage/DNA Repair compound Library Cell Cycle compound library	Click to Expand

Signaling Pathway

DNA/RNA Synthesis Signaling Pathway

Cell Culture and Working Concentration

Cell Lines	Assay Type	Activity Description	PMID
SJ-GBM2	qHTS assay	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
A673	qHTS assay	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
Click to View More Cell Line Experimental Data

Mechanism of Action

In vitro
In vitro	Ifosfamide (50 mM) increases CYP3A4, CYP2C8, and CYP2C9 protein levels in hepatocytes, which thereby enhances their own rates of 4-hydroxylation in the cultured hepatocytes. This compound only induces CYP3A4 in one human hepatocyte culture that contained the polymorphically expressed CYP3A5 in addition to the more widely expressed CYP3A4. ^[1] It is a prodrug metabolised in the liver by cytochrome P450 mixed-function oxidase enzymes to isofosforamide mustard, the active alkylating compound. This drug has produced favourable response rates in small cell lung cancer, paediatric solid tumours, non-Hodgkin's and Hodgkin's lymphoma, and ovarian cancer. ^[2] It is highly cytotoxic to MCF-7 cells following stable transfection of CYP2B1 but exhibits no toxicity to parental tumor cells or to a beta-galactosidase-expressing MCF-7 transfectant, this cytotoxicity could be appreciably blocked by the CYP2B1 inhibitor metyrapone. ^[3] When combined with Zoledronic acid, it is more effective than each agent alone in preventing tumor recurrence, improving tissue repair, and increasing bone formation as revealed by the analysis of trabecular architecture. ^[4]

In Vivo
In vivo	Ifosfamide (100 mg/kg, 200 mg/kg and 400 mg/kg) injected intraperitoneally induces a dose dependent increase in bladder wet weight and Evans blue extravasation in mice. This compound reveals extensive cystitis characterized by acute inflammation with vascular congestion, edema, hemorrhage and fibrin deposition, neutrophil cell infiltration and epithelial denudation in mice. It shows intense reactivity to inducible nitric oxide synthase in the cytoplasm as well as intense and diffuse necrosis on hematoxylin and eosin staining. ^[5]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT04925089	Recruiting	Leiomyosarcoma	University of Michigan Rogel Cancer Center\|National Cancer Institute (NCI)	April 26 2023	--
NCT04968106	Recruiting	Resectable Sarcoma	Institut Bergonié\|Incyte Biosciences International Sàrl	December 7 2022	Phase 2
NCT02432274	Completed	Tumors\|Solid Malignant Tumors\|Osteosarcoma\|Differentiated Thyroid Cancer (DTC)	Eisai Limited\|Merck Sharp & Dohme LLC\|Eisai Inc.	December 29 2014	Phase 1\|Phase 2

References

https://pubmed.ncbi.nlm.nih.gov/9157990/
https://pubmed.ncbi.nlm.nih.gov/1720382/
https://pubmed.ncbi.nlm.nih.gov/8640822/

https://pubmed.ncbi.nlm.nih.gov/15894525/
https://pubmed.ncbi.nlm.nih.gov/11956484/

+ Expand

Chemical Information

Molecular Weight	261.09	Formula	C₇H₁₅Cl₂N₂O₂P
CAS No.	3778-73-2	SDF	Download SDF
Synonyms	NSC109724, Isophosphamide
Smiles	C1CN(P(=O)(OC1)NCCCl)CCCl

Storage and Stability

Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
			1 month-20°Cin solvent

In vitro
Batch:

DMSO : 52 mg/mL ( (199.16 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 52 mg/mL

Ethanol : 52 mg/mL

Molecular Weight Calculator

In vivo Batch: Add solvents to the product individually and in order.				In vivo Formulation Calculator
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.600mg/ml (9.96mM)	Taking the 1 mL working solution as an example, add 50 μL of 52 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.260mg/ml (1.00mM)	Taking the 1 mL working solution as an example, add 50 μL of 5.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):